Overview

Lifyorli is approved by the U.S. Food and Drug Administration (FDA) in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, with at least one prior regimen that included bevacizumab. Lifyorli is also known by its drug name, relacorilant.

Lifyorli is a glucocorticoid receptor antagonist. Scientists believe it works by blocking the glucocorticoid receptor, which may help reduce tumor-supporting effects of cortisol-related signaling and improve the anticancer activity of nab-paclitaxel in platinum-resistant ovarian cancer.

How do I take it?

Prescribing information states that Lifyorli is taken by mouth as an oral capsule in combination with nab-paclitaxel. It is taken once on the day before, the day of, and the day after each nab-paclitaxel infusion, and it should be taken exactly as prescribed by a healthcare provider.

Side effects

Common side effects of Lifyorli include decreased hemoglobin, decreased neutrophils (a low level of infection-fighting white blood cells), fatigue, nausea, diarrhea, decreased platelets (cells that help blood clot), rash, and decreased appetite.

Rare but serious side effects may include neutropenia (very low levels of infection-fighting white blood cells) and severe infections, adrenal insufficiency (when the body does not make enough stress hormone), worsening of conditions treated with glucocorticoids because Lifyorli can make those medicines less effective, and embryo-fetal toxicity (harm to a developing fetus during pregnancy).

For more information about this treatment, visit:

Lifyorli (Relacorilant) Capsules, for Oral Use — Corcept Therapeutics